Holen Sie sich die Stockscreener-App
8.91
1.70%
-0.18
Handel nachbörslich:
8.92
0.010
+0.11%
Schlusskurs vom Vortag:
$9.09
Offen:
$9.09
24-Stunden-Volumen:
517.01K
Relative Volume:
0.58
Marktkapitalisierung:
$575.53M
Einnahmen:
$262.60M
Nettoeinkommen (Verlust:
$-80.80M
KGV:
-7.3267
EPS:
-1.2161
Netto-Cashflow:
$-275.70M
1W Leistung:
+4.51%
1M Leistung:
-14.41%
6M Leistung:
-28.06%
1J Leistung:
+37.26%
1-Tages-Spanne:
$8.895
$9.179
1-Wochen-Bereich:
$8.4529
$9.34
52-Wochen-Spanne:
$6.055
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
8.92 | 586.50M | 262.60M | -80.80M | -275.70M | -1.2161 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-10-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-09-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Arvinas Q1 earnings call highlights - MSN
Arvinas (ARVN) CEO reports small automatic share sale for RSU tax withholding - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas (NASDAQ: ARVN) insider sells shares; RSU settlement reported - Stock Titan
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Arvinas Employees Give Back During Company-wide Impact Day - Sahm
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts - Investing.com India
Arvinas staff spend a day cooking, cleaning and crafting for patients and kids - Stock Titan
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
These analysts increase their forecasts on Arvinas after Q1 results - MSN
Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Arvinas Holding Company (ARVN) - The Globe and Mail
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN) - Sahm
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - Moomoo
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - Yahoo Finance
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
HC Wainwright Comments on Arvinas' Q2 Earnings (NASDAQ:ARVN) - MarketBeat
Wedbush Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $11 - Moomoo
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
BofA Securities Raises Price Target on Arvinas to $16 From $14 - marketscreener.com
These Analysts Increase Their Forecasts On Arvinas After Q1 Results - Sahm
Vanguard Group Inc. Sells 1,331,629 Shares of Arvinas, Inc. $ARVN - MarketBeat
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, ArvinasHas The Bull Case Changed? - Yahoo Finance
Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet - MSN
Randy Teel Sells 9,657 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Insider Selling: Arvinas (NASDAQ:ARVN) CAO Sells 1,919 Shares of Stock - MarketBeat
Insider Selling: Arvinas (NASDAQ:ARVN) Insider Sells 11,108 Shares of Stock - MarketBeat
Arvinas president and CEO Randy Teel sells $95,965 in stock By Investing.com - Investing.com Canada
Arvinas CSO Angela Cacace sells $95,965 in company stock By Investing.com - Investing.com India
Arvinas president and CEO Randy Teel sells $95,965 in stock - Investing.com
Arvinas CSO Angela Cacace sells $95,965 in company stock - Investing.com
Arvinas CFO Andrew Saik sells $110,692 in company shares By Investing.com - Investing.com South Africa
Arvinas CFO Andrew Saik sells $110,692 in company shares - Investing.com
Arvinas (ARVN) CFO sells 11,139 shares to cover RSU taxes - Stock Titan
Arvinas (ARVN) VP Loomis has 1,919 shares sold to cover RSU taxes - Stock Titan
Arvinas (ARVN) CSO share sale covers RSU tax withholding - Stock Titan
Arvinas (ARVN) CMO share sale covers RSU tax withholding - Stock Titan
Automatic tax sale trims Arvinas (NASDAQ: ARVN) CEO share holdings - Stock Titan
BofA raises Arvinas stock price target on Veppanu out-licensing deal By Investing.com - Investing.com South Africa
BTIG raises Arvinas stock price target on commercial partnership By Investing.com - Investing.com India
BofA raises Arvinas stock price target on Veppanu out-licensing deal - Investing.com Nigeria
Goldman Sachs Maintains Arvinas(ARVN.US) With Sell Rating, Maintains Target Price $6 - Moomoo
H.C. Wainwright Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
ARVN Maintained by Barclays -- Price Target Raised to $20 - GuruFocus
Arvinas anticipates US ARV-102 PSP trial by end of 2026 while maintaining cash runway into second half of 2028 - MSN
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):